Current Trend: XBiotech (NASDAQ: XBIT)

EPS growth is an important number as it indicates the future prospects of XBiotech. I will do my best to analyze this stock, but there is limited information, therefore please check back later by doing a search here or going to the tag page for the stock symbol XBIT here. Growth in EPS is an important measure of administration performance because it shows how much money XBiotech is making for it’s investors or shareholders.

XBiotech is part of the biotechnology industry and is part of the healthcare sector. The company CEO is John Simard. XBiotech Inc is engaged in discovering and developing True Human antibody technology monoclonal antibodies for treating a variety of diseases.

Previous Intraday Performance:

The XBIT shares had a previous change of 2.33% which opened at 6.52 and closed at 6.60. It moved to an intraday high of 6.60 and a low of 6.38.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa

Historical Performance:

Over the last five trading days, XBIT shares returned 8.73% and in the past 30 trading days it returned 35.25%. Over three months, it changed 72.77%. In one year it has changed 34.69% and within that year its 52-week high was 6.63 and its 52-week low was 2.13. XBIT stock is 209.86% above its 52 Week Low.

Our calculations result in a 200 day moving average of 4.30 and a 50 day moving average of 5.07. Right now, XBIT stock is trading 53.62% above its 200 day moving average.

SeekingAlpha:  Subcutaneous formulation of XBiotech’s bermekimab successful in mid-stage study


The company has a market cap of $236.4m with 35.8m shares outstanding and a float of 25.8m shares. Trading volume was 48,904 shares and has experienced an average volume of 129,344 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for XBiotech was -0.99 which ended on 31st of December 2017.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.14
06-30-2018:  0.00
03-31-2018:  0.00
12-31-2017:  0.00

Indicators Also to Watch:

Based on the latest filings, there is 8.80% of institutional ownership.

I calculated the beta to be 0.22

SeekingAlpha:  Subcutaneous formulation of XBiotech’s bermekimab successful in mid-stage study

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -39.29%, return on assets is -37.38% and price-to-book is 4.92.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Tags: , , ,

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *